Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202631847

Alkaline Phosphatase in Clinical Laboratory Medicine: Biochemistry, Isoenzymes, and Diagnostic Applications-An Updated Review.

Hamdan Ali Alshehri[(1)] , Renad A. Saigh[(2)] , Raheem M. Balkhtb[(3)] , Faisal Ali Naif Alanazi[(3)] , Alaa Salman Jubran Khubrani[(4)] , Latifa Fareed Althawab[(3)] , Asma Ghzzai Almutairi Almutairi[(3)] , Lina Nabhan[(3)] , Maryam Mohammed Alqahtani[(3)] , Shahad Abdulrahman Alluhaymid[(3)]

(1)King Abdullah bin Abdulaziz University Hospital, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, Ministry of Education, Saudi Arabia
(2)Department of Laboratories and Blood Bank, Jazan University Hospital, Jazan University, University Medical City, Jazan 82817, Saudi Arabia, Ministry of Education, Saudi Arabia
(3)Security Forces Hospital, Riyadh, Saudi Arabia, Ministry of Interior, Saudi Arabia
(4)Jazan Regional Laboratory, Jazan, Saudi Arabia, Ministry of Health, Saudi Arabia

Abstract

Background: Alkaline phosphatase (ALP) is an important clinical laboratory enzyme associated primarily with hepatobiliary function and bone metabolism. Abnormal serum ALP activity may indicate cholestatic liver disease, increased bone turnover, or other physiological and pathological conditions. Accurate measurement and interpretation are therefore essential for appropriate clinical decision-making.

Aim: This review examines the biochemical characteristics of ALP, its physiological and pathological variations, laboratory measurement techniques, diagnostic applications, and clinical significance, with emphasis on quality control and laboratory safety.

Methods: A narrative review approach was used to summarize published information on ALP biochemistry, tissue-specific isoenzymes, specimen requirements, analytical methods, interfering factors, quality assurance, and clinical interpretation. Relevant diagnostic applications and laboratory practices were also examined.

Results: Serum ALP originates mainly from hepatic and bone tissues, although intestinal, placental, and other isoenzymes may contribute to circulating activity. Increased ALP is particularly associated with cholestasis, biliary obstruction, infiltrative liver diseases, and disorders involving increased bone turnover. GGT and 5'-nucleotidase measurements, alongside isoenzyme analysis, help establish the tissue source. Analytical accuracy depends on appropriate specimen collection, validated measurement procedures, reagent quality, and effective internal and external quality control. Biological variation, medications, hemolysis, lipemia, and assay-specific interference may affect results.

Conclusion: ALP remains a valuable biochemical marker for evaluating hepatobiliary and skeletal disorders. Reliable clinical interpretation requires integration of laboratory findings with patient characteristics, complementary investigations, and appropriate quality management.

Keywords: Alkaline phosphatase; ALP isoenzymes; Clinical biochemistry; Cholestasis; Bone metabolism; Laboratory diagnosis; Quality control.

Introduction

Alkaline phosphatase (ALP) is a group of membrane-associated isoenzymes that catalyze the hydrolysis of organic phosphate esters in the extracellular environment. The enzyme requires zinc and magnesium ions as essential cofactors for its catalytic activity. Although ALP isoenzymes are distributed across several tissues and exhibit different physicochemical characteristics, they share the ability to catalyze the same biochemical reaction. In hepatocytes, ALP is located in the cytosol and along the canalicular membrane, where it contributes to processes associated with hepatic function and biliary physiology [1]. ALP is expressed in several organs, particularly the liver, bone, intestine, placenta, kidneys, and germinal tissues. More than 80% of circulating serum ALP originates from the liver and bone, while the intestine contributes a smaller proportion. Despite its widespread distribution and established diagnostic importance, the enzyme's complete physiological functions remain incompletely understood [2]. ALP isoenzymes are classified into tissue-specific and tissue-nonspecific forms. Tissue-specific isoenzymes include intestinal, placental, and germinal tissue ALP, which are normally expressed in their corresponding tissues but may enter the circulation under particular physiological or pathological conditions [3]. Tissue-nonspecific ALP is clinically important because it accounts for most circulating serum ALP activity. It

*Corresponding author Haalshehri21@gmail.com (Hamdan Ali Alshehri).
Receive Date: 30 August 2026, Revise Date: 27 October 2026, Accept Date: 15 November 2026

is encoded by a single gene and primarily expressed in the liver, bone, and kidneys [4]. Differences in carbohydrate and lipid side chains, resulting from posttranslational modifications, contribute to the distinct physicochemical properties of ALP isoenzymes despite their shared amino acid sequence. Increased intestinal ALP production has also been reported in certain pathological conditions, including Hodgkin lymphoma [5,6]. Understanding these characteristics is essential for accurate laboratory measurement and clinical interpretation of serum ALP.

Etiology and Epidemiology

Serum alkaline phosphatase (ALP) concentrations are influenced by several physiological factors, including age, sex, body composition, lifestyle, and nutritional status. Age is particularly important when interpreting ALP measurements because circulating enzyme levels change throughout life. Concentrations are highest during childhood and puberty, reflecting increased osteoblastic activity associated with skeletal growth and development. Following the completion of skeletal maturation, serum ALP levels gradually decline. Between 15 and 50 years of age, this reduction is slightly more pronounced in males than in females. In older individuals, ALP concentrations may increase again, with differences observed between men and women. The biological mechanisms responsible for these age-related and sex-related variations have not been fully established [1]. Other factors may also contribute to variations in serum ALP activity among healthy individuals. Research has demonstrated a positive association between ALP concentrations and body weight and smoking, whereas an inverse relationship has been reported with height. These findings indicate that individual characteristics should be considered when interpreting laboratory results and distinguishing physiological variations from pathological elevations [7]. In healthy populations, the liver and bone represent the principal sources of circulating ALP. A smaller proportion may originate from the intestinal tract, depending on individual physiological characteristics [8]. Dietary intake can temporarily influence serum ALP measurements. In particular, consumption of a fatty meal may increase intestinal ALP activity in individuals with blood groups O and B. This postprandial elevation may persist for approximately 12 hours, potentially affecting the interpretation of laboratory findings. Therefore, fasting blood collection is recommended when accurate assessment of serum ALP concentrations is required, particularly when investigating unexplained elevations or monitoring changes over time [9]. Understanding these physiological influences helps clinical laboratory professionals interpret ALP results accurately and avoid unnecessary diagnostic investigations.




Figure-1: Etiology and Epidemiology of Alkaline phosphatase.

Pathophysiology

Human alkaline phosphatase (ALP) is attached to the outer surface of cell membranes through a glycosylphosphatidylinositol (GPI) anchor. Its release into the circulation occurs through the action of specific phospholipase enzymes, which cleave this membrane attachment and allow ALP to enter the extracellular compartment and subsequently the serum [10]. Circulating ALP has an estimated half-life of approximately seven days. Its clearance is largely independent of biliary drainage and overall hepatic function, although the precise anatomical site and mechanisms responsible for its degradation remain incompletely understood. Consequently, serum ALP concentrations may remain elevated for approximately one week after the resolution of biliary obstruction, reflecting the time required for the circulating enzyme to be cleared [1]. The liver represents the most common source of pathological increases in serum ALP, particularly in patients with hepatobiliary disorders. Increased osteoblastic activity is another important contributor, especially in individuals with active bone growth, metabolic bone diseases, fractures, or other conditions associated with accelerated bone formation. During the late third trimester of pregnancy, placental ALP enters the maternal circulation and contributes substantially to the physiological elevation of total serum ALP [11].

The mechanisms responsible for increased ALP concentrations in hepatobiliary diseases are primarily associated with enhanced enzyme synthesis rather than impaired biliary excretion. Bile acid accumulation during cholestasis stimulates hepatic ALP production, partly through increased translation of ALP messenger RNA. The newly synthesized enzyme subsequently enters the circulation through processes that may involve canalicular leakage toward the hepatic sinusoids. However, the exact mechanisms regulating this release have not been completely established [1,11]. Studies have also identified circulating vesicles containing ALP and other membrane-associated enzymes in patients with cholestasis. This finding supports the involvement of membrane-derived vesicles in enzyme release.

Importantly, serum ALP may remain within the reference range during the early stages of acute biliary obstruction, even when aminotransferase concentrations have already increased substantially. This delayed elevation reflects the time required for increased hepatic enzyme synthesis and subsequent release into the bloodstream [12]. These mechanisms explain the diagnostic importance of interpreting ALP alongside other liver function tests and the patient's clinical presentation.

Specimen Requirements and Procedure

Accurate measurement of serum alkaline phosphatase (ALP) activity depends on appropriate patient preparation, specimen collection, handling, and storage. Blood collection is generally recommended after a minimum fasting period of eight hours to minimize the influence of recent food intake on circulating ALP concentrations, particularly the intestinal isoenzyme. Both serum and heparinized plasma are acceptable specimens and generally produce comparable analytical results when processed using validated laboratory methods. Minor hemolysis may be tolerated; however, grossly hemolyzed specimens should be avoided because excessive cellular disruption can interfere with laboratory measurements and compromise result reliability [13]. Specimen storage conditions are particularly important because ALP activity may change during storage and subsequent temperature variations. Fresh serum samples may demonstrate an increase in enzyme activity of approximately 2% within six hours when maintained at 25 °C. More substantial increases, reaching approximately 30%, have been reported following the thawing of frozen serum samples or reconstitution of lyophilized specimens. These changes may result from the release of ALP previously associated with lipoprotein complexes or from increased catalytic activity of the unbound enzyme. Furthermore, refrigerated or frozen specimens may exhibit increased measured activity after warming to room temperature. Such changes can introduce analytical variability and affect the interpretation of results, particularly when serial measurements are compared [13,14]. For optimal analytical accuracy, ALP specimens should preferably undergo laboratory analysis on the same day as collection. If immediate analysis is not possible, laboratories should follow validated storage and temperature-control procedures to minimize changes in enzyme activity. Specimen handling should remain consistent between collection and analysis. Blood collection should follow standard phlebotomy procedures. Acceptable collection tubes include plain red-top tubes and speckled red-top tubes containing a gel separator. To minimize contamination from anticoagulants and additives, tubes containing anticoagulants should not be collected before serum collection tubes. Appropriate tube selection, correct collection order, proper labeling, and timely transportation are essential components of preanalytical quality assurance [15]. Clinical laboratory professionals should document any deviations from recommended collection or storage conditions and assess their potential effects before reporting ALP results. These measures help maintain specimen integrity and improve the reliability of biochemical assessment.

Diagnostic Tests

Several analytical methods are available for measuring serum alkaline phosphatase (ALP) activity in clinical laboratories. These methods differ according to the phosphate ester substrate, the alkaline buffer system, reaction conditions, and reference intervals established for each analytical procedure. Most routine assays are based on the ability of ALP to catalyze the hydrolysis of phosphate esters under alkaline conditions. The resulting reaction products are measured to determine the enzyme's catalytic activity in the patient's specimen [16]. The most widely adopted international method uses para-nitrophenyl phosphate (p-nitrophenyl phosphate) as the artificial substrate and an amino alcohol as the buffering agent. ALP hydrolyzes this substrate, producing para-nitrophenol, which generates a measurable color change under alkaline conditions. The rate of product formation is proportional to the enzymatic activity in the specimen and is measured spectrophotometrically. Results are commonly reported in international units per liter (IU/L), representing the amount of enzyme that catalyzes a defined reaction under specified analytical conditions [17]. Quality control procedures, calibration, temperature standardization, and appropriate reference intervals are essential for maintaining the accuracy and reproducibility of these measurements. Different analytical methods generally demonstrate comparable clinical performance in detecting abnormal ALP activity associated with hepatobiliary and bone disorders. However, differences in substrates, buffers, and assay conditions may produce variations in absolute results. Therefore, interpreting ALP concentrations relative to the upper limit of the reference range is useful when comparing results obtained using different laboratory methods. Expressing an elevation as a multiple of the upper limit of normal also helps assess the magnitude of enzyme abnormalities across different clinical settings [18].

When total ALP activity is elevated, additional investigations may be required to identify the tissue responsible for the increase. Electrophoresis can separate ALP isoenzymes according to their migration characteristics, although liver and bone isoenzymes have similar electrophoretic mobility and may not be reliably distinguished using electrophoresis alone. Combining cellulose acetate electrophoresis with heat

inactivation improves differentiation between these fractions. Polyacrylamide gel slab electrophoresis provides greater analytical specificity and is considered a highly accurate approach for identifying liver, bone, intestinal, and placental ALP isoenzymes. However, its availability remains limited in routine clinical laboratories [19]. The selection of an appropriate diagnostic method depends on laboratory resources, clinical requirements, and the need to distinguish between specific ALP isoenzymes. Combining total ALP measurement with complementary biochemical and isoenzyme investigations supports accurate diagnosis and clinical interpretation.

Testing Procedures

Serum alkaline phosphatase (ALP) activity is routinely measured using semiautomatic or fully automated clinical chemistry analyzers based on photometric principles. Photometry determines analyte concentrations by measuring light absorption across ultraviolet, visible, or infrared wavelengths. In these systems, a specific light source passes radiation through the reaction mixture, while optical detectors convert transmitted light into electrical signals proportional to its intensity. Common detectors include photodiodes, photoresistors, and photomultiplier tubes [20]. Quantitative analysis relies on the Beer-Lambert law, which establishes a relationship between absorbance and analyte concentration. Test-specific calibration functions allow analyzers to calculate ALP activity accurately and reproducibly [21]. When total ALP activity is elevated, additional procedures may be required to identify its tissue origin. Electrophoresis is commonly used to separate the four principal isoenzyme fractions, namely liver, bone, placental, and intestinal ALP. Their electrophoretic migration generally follows the order of liver, bone, placental, and intestinal fractions. However, the similarity between liver and bone isoenzymes can produce overlapping bands, making accurate quantification difficult. Combining electrophoresis with complementary separation methods improves differentiation. Direct immunochemical assays are also available for measuring bone-specific ALP [19,22,23].

The hepatic fraction can be further divided into the major liver band and a smaller fast-liver fraction, also known as α1-liver ALP. The fast-liver fraction migrates anodally relative to the major hepatic band. The major liver fraction commonly accounts for increased ALP activity in hepatobiliary disorders and may become elevated early in disease progression. The fast-liver fraction has been associated with metastatic liver carcinoma and other hepatobiliary conditions. Although it may suggest obstructive liver disease, its presence does not always indicate an identifiable pathological condition [24,25]. Heat inactivation provides another method for distinguishing ALP isoenzymes. Serum activity is measured before and after heating at 56 °C for 10 minutes. Residual activity below 20% generally suggests a predominantly bone-derived elevation, whereas activity exceeding 20% favors a hepatic contribution. Heat stability differs among isoenzymes, decreasing in the following order: placental, intestinal, liver, and bone. Placental ALP demonstrates considerable resistance to thermal denaturation and may remain active after exposure to 65 °C for 30 minutes [11,26]. However, this technique has limitations because results depend on accurate temperature control, incubation time, and assay sensitivity. Overlapping heat-stability patterns between liver and bone fractions may also reduce diagnostic accuracy [27].

Selective chemical inhibition represents a third approach. Phenylalanine inhibits intestinal and placental ALP more strongly than liver and bone fractions. However, it cannot reliably distinguish between intestinal and placental isoenzymes or between hepatic and bone isoenzymes [28]. Abnormal ALP fractions may also occur in association with malignancies. The Regan and Nagao isoenzymes are classified as carcinoplacental ALP variants because of their similarities to placental ALP [29]. Regan ALP exhibits marked heat stability, remaining active after heating at 65 °C for 30 minutes. It migrates similarly to bone ALP and is inhibited by phenylalanine [30]. Nagao ALP shares these electrophoretic, thermal, and inhibitory characteristics but is additionally inhibited by L-leucine. It has been identified in metastatic pleural carcinoma and pancreatic and biliary adenocarcinomas [31,32]. The selection of testing procedures depends on laboratory availability and diagnostic requirements. Combining total ALP measurement with electrophoretic, immunochemical, or complementary analytical techniques provides a more reliable assessment of isoenzyme distribution and potential underlying disease.




Figure-2: Testing procedures of ALP.

Interfering Factors

Several preanalytical, analytical, and physiological factors can influence serum alkaline phosphatase (ALP) measurements. Metal-chelating anticoagulants, including EDTA, citrate, and oxalate, should be avoided because they bind magnesium and zinc, which are essential cofactors for ALP activity.

Hemolyzed or lipemic specimens may also interfere with measurements by increasing background absorbance and should be rejected when interference is significant. Bilirubin concentrations up to 20 mg/dL have been reported not to affect certain ALP assays.[33] The composition and purity of assay reagents are equally important. Diethanolamine (DEA), commonly used in transphosphorylation buffers, may contain monoethanolamine (MEA), a potent ALP inhibitor. DEA solutions can also degrade during storage, generating additional MEA and reducing measured enzyme activity. Commercial *p*-nitrophenyl phosphate substrate preparations may contain excessive *p*-nitrophenol or inorganic phosphate. The former increases blank absorbance, whereas the latter inhibits ALP activity, potentially producing inaccurate results.[34,35] Physiological conditions, medications, herbal products, dietary habits, smoking, alcohol consumption, and pregnancy can alter circulating ALP activity. More than 1,000 drugs, herbal preparations, and physiological conditions have been associated with changes in ALP levels. Clofibrate, for example, may reduce total ALP activity and several isoenzyme fractions, with a relatively limited effect on the liver fraction. This reduction may be related to increased biliary clearance of the enzyme.[36] Hormonal effects are variable. Estrogens may suppress ALP activity by reducing bone turnover, although studies have also reported increased activity following estrogen or androgen exposure.[37]

Certain cardiovascular medications may influence ALP through changes in bone metabolism. Verapamil administration for two months has been associated with increased total and bone-specific ALP activity in hypertensive patients. This effect may involve increased parathyroid hormone secretion and subsequent changes in bone turnover.[38] In addition, hepatotoxic medications and drugs that induce cholestasis can increase serum ALP, particularly when they cause hepatobiliary injury or impaired bile flow.[39] Spectrophotometric interference requires particular attention. Alkali denaturation of hemoglobin may produce a negative absorbance offset, resulting in falsely reduced ALP measurements. Icterus can also interfere with colorimetric assays because bilirubin absorbs light within the 400–540 nm range, with maximum absorption near 460 nm. Consequently, assays using primary or secondary absorbance measurements within this range may produce inaccurate results. The extent of interference depends on the assay design and bilirubin concentration. Conjugated and unconjugated bilirubin may affect individual methods differently, with conjugated bilirubin producing more pronounced interference in certain assays.[40,41] Laboratories should therefore consider specimen quality, reagent integrity, medication history, physiological conditions, and assay-specific interference when interpreting ALP results.

Results, Reporting, and Critical Findings

Interpretation of alkaline phosphatase (ALP) results requires consideration of the patient's clinical condition, age, sex, physiological status, and other biochemical findings. An isolated elevation in ALP, particularly when serum aminotransferases remain within their reference ranges, requires further investigation to establish the underlying cause. Similarly, when ALP increases disproportionately compared with other liver biochemical markers, clinicians should determine whether the elevation originates from the liver, bone, or another tissue. This approach is particularly important in asymptomatic patients, in whom an isolated abnormal result may represent an early manifestation of hepatobiliary disease, increased bone turnover, or a physiological variation.[10] The principal circulating ALP isoenzymes originate from the liver, bone, placenta, and intestine. These isoenzymes possess distinct physicochemical characteristics that allow their differentiation through specialized laboratory techniques. Identifying the tissue responsible for increased ALP activity helps guide subsequent investigations and prevents unnecessary diagnostic procedures. The interpretation should also consider whether the elevation is transient or persistent and whether it is associated with symptoms, medication exposure, pregnancy, or an underlying metabolic or hepatobiliary disorder.[42] Measurement of additional enzymes, particularly gamma-glutamyl transferase (GGT) and 5'-nucleotidase (5NT), provides a practical approach to determining whether an elevated ALP concentration has a hepatic origin. Both enzymes commonly increase in hepatobiliary disorders and may rise alongside liver-derived ALP. In contrast, bone disorders generally do not produce corresponding increases in GGT or 5NT. GGT is a sensitive marker of biliary tract abnormalities and is frequently used to support the hepatic origin of elevated ALP. However, its specificity is relatively limited because increased GGT activity can occur in several conditions unrelated to primary liver disease. Therefore, GGT should be interpreted alongside other biochemical markers and the patient's clinical findings rather than used as an independent diagnostic indicator.[43]

Serum 5NT provides another useful marker for evaluating suspected hepatobiliary disease. In nonpregnant individuals, increased 5NT activity is relatively specific for hepatic disorders and generally correlates with ALP of hepatic origin. However, pregnancy may also be associated with increased 5NT activity, which should be considered when interpreting results. Importantly, normal 5NT activity does not completely exclude hepatobiliary disease in patients with elevated ALP. These enzymes may not increase simultaneously, particularly during the early

stages of hepatic injury or in relatively mild disease. Consequently, a normal 5NT result should not override other clinical or biochemical evidence suggesting hepatobiliary involvement.[44] Laboratory reports should include the measured ALP activity, the applicable reference interval, and an indication of whether the result is elevated or reduced. When appropriate, results should be interpreted in relation to GGT, 5NT, aminotransferases, bilirubin, and other relevant biochemical findings. Persistent or unexplained elevations may require ALP isoenzyme analysis or bone-specific ALP measurement. Marked elevations, progressive increases, or abnormalities accompanied by clinical evidence of liver or bone disease warrant timely clinical assessment. Integrating biochemical results with patient history and confirmatory testing improves diagnostic accuracy and supports appropriate clinical management.

Clinical Significance

Serum alkaline phosphatase (ALP) measurement is particularly important in evaluating cholestatic liver diseases. Marked elevations are frequently observed in patients with intrahepatic or extrahepatic cholestasis. Approximately 75% of affected patients may exhibit ALP levels at least four times the upper limit of normal (ULN). However, the magnitude of elevation cannot reliably distinguish between intrahepatic and extrahepatic causes.[10] Marked ALP elevations may occur in biliary obstruction caused by malignancies, including cholangiocarcinoma, pancreatic head adenocarcinoma, and ampullary adenocarcinoma. Benign obstructive conditions, such as choledocholithiasis, biliary strictures, and sclerosing cholangitis, can produce similar biochemical abnormalities. Intrahepatic causes include primary biliary cholangitis (PBC), drug-induced liver injury, chronic rejection following liver transplantation, and infiltrative diseases such as sarcoidosis, amyloidosis, tuberculosis, and hepatic metastases. Severe alcoholic hepatitis associated with steatonecrosis may also produce substantial ALP elevations.[45] Patients with acquired immunodeficiency syndrome (AIDS) may develop markedly increased ALP activity, particularly in association with AIDS-related cholangiopathy. This condition may result from opportunistic infections, including cytomegalovirus and cryptosporidiosis, or granulomatous hepatic involvement caused by tuberculosis.[46]

Moderate ALP elevations, generally reaching up to four times the ULN, are less specific and may accompany several hepatic and systemic disorders. Hepatic causes include cirrhosis, chronic hepatitis, viral hepatitis, congestive heart failure, and ischemic cholangiopathy.[47] Nonhepatic conditions may also increase circulating ALP, including intra-abdominal infections, sepsis-associated cholestasis, Hodgkin lymphoma, myeloid metaplasia, and osteomyelitis.[10] Therefore, an elevated result should not automatically be interpreted as evidence of primary liver disease. Malignancies can increase serum ALP through several mechanisms. Primary or metastatic tumors may obstruct bile ducts or increase the release of hepatic ALP into the circulation.[48] Some tumors can also produce abnormal ALP isoenzymes. For example, Hodgkin lymphoma may secrete the Regan isoenzyme, a tumor-associated form of placental ALP. Other malignancies produce paraneoplastic effects that increase hepatic ALP without direct liver involvement. Stauffer syndrome, associated with renal cell carcinoma, represents an example of this mechanism.[49] Reduced ALP activity also has clinical significance. Low serum levels may occur in Wilson disease, particularly during fulminant hepatic presentations accompanied by hemolysis. Excess copper may interfere with zinc availability, reducing the activity of this zinc-dependent enzyme.[50] Other causes include zinc deficiency, pernicious anemia, hypothyroidism, and congenital hypophosphatasia. These conditions should be considered when ALP remains below the reference range, particularly when compatible clinical or biochemical findings are present.[51]

Transient hyperphosphatasemia is another recognized pattern, particularly in children. It involves a temporary and sometimes substantial increase in serum ALP, occasionally reaching 30 times the ULN. Either bone or liver ALP isoenzymes may contribute to this elevation.[52] Affected children are generally asymptomatic and have unremarkable medical histories, physical examinations, and other laboratory findings. A recent mild viral illness may precede the abnormality in some cases. The elevation usually resolves spontaneously, although its precise clinical significance remains uncertain.[53] The extent of ALP elevation helps determine the need for further investigation. Patients with mild increases, defined as less than 50% above the ULN, generally do not require extensive immediate evaluation. Periodic clinical assessment and repeat liver biochemical testing may be sufficient. In contrast, marked or persistent elevations require investigation to establish whether the source is hepatic or nonhepatic.[54] Concurrent increases in GGT or 5'-nucleotidase (5NT) support a hepatobiliary origin. When the elevation is nonhepatic, investigations should focus on the relevant tissue source. Increased bone-derived ALP may occur in Paget disease, bone metastases, osteogenic sarcoma, healing fractures, hyperparathyroidism, hyperthyroidism, and osteomalacia. Intestinal ALP may increase following fatty meals or occur as a hereditary biochemical variant. In the absence of other abnormalities, this intestinal fraction generally does not require additional investigation.[55] When a hepatic origin is suspected, evaluation should include biliary imaging and a review of the patient's medication history to identify possible drug-induced cholestasis. Right

upper quadrant ultrasonography is usually the initial imaging investigation. If bile duct dilation is identified, magnetic resonance cholangiopancreatography or endoscopic retrograde cholangiopancreatography may be selected according to the clinical presentation and need for intervention. If the bile ducts are not dilated, serum antimitochondrial antibodies (AMA) should be measured to investigate PBC.[45,56] When AMA testing is negative, further assessment should consider AMA-negative PBC, sarcoidosis, other infiltrative disorders, and alternative causes of intrahepatic cholestasis. Liver biopsy may ultimately be required when noninvasive investigations do not establish the diagnosis. Histological examination can help identify the underlying hepatic pathology and guide subsequent management.[57]




Figure-3: Clinical Significance of ALP.

Quality Control and Lab Safety

A quality management system (QMS) is essential for maintaining the accuracy, reliability, and timeliness of laboratory results. It provides a structured framework for monitoring laboratory operations, identifying errors, and ensuring that testing procedures meet established performance standards. An inadequate QMS may lead to incorrect clinical decisions, delayed diagnoses, inappropriate treatment, and unnecessary investigations. Effective implementation integrates quality control (QC), quality assurance, staff responsibilities, and continuous performance evaluation.[58,59] Internal quality control involves monitoring analytical procedures to ensure that patient results meet predefined performance specifications. Control materials with known or assigned values are analyzed alongside patient specimens to assess the stability and reliability of the testing system. Results within established acceptance limits indicate that the analytical process is functioning as expected and that patient results are suitable for reporting. Conversely, QC results outside acceptable limits suggest possible analytical errors, requiring investigation and corrective action before patient results are released.[60,61] Corrective measures may include checking reagents, recalibrating the analyzer, inspecting equipment, reviewing maintenance records, and repeating control measurements. Once the source of the problem has been identified and resolved, affected patient samples should be reanalyzed. If inaccurate results have already been reported, the laboratory must issue corrected reports and communicate significant changes to the responsible clinicians.[62]

For non-waived testing, laboratories are generally required under applicable regulations to analyze at least two levels of control materials every 24 hours. Additional QC testing may be necessary after calibration, maintenance, reagent replacement, or other events that could affect analytical performance. Laboratories may also develop individualized QC plans based on risk assessment, particularly when manufacturer recommendations differ from regulatory requirements. These plans identify potential errors across preanalytical, analytical, and postanalytical stages and establish appropriate monitoring procedures. Patient-based statistical quality monitoring can provide an additional means of detecting changes in analytical performance.[63,64] The Levey-Jennings chart is widely used to monitor internal QC results. It displays control measurements sequentially against the established mean and standard deviation limits. Under stable analytical conditions, results are expected to distribute around the mean, with most measurements occurring within one or two standard deviations. Systematic shifts, trends, or unusually scattered results may indicate analytical instability. Westgard multirule procedures provide standardized criteria for interpreting QC patterns and identifying random or systematic errors. Applying these rules helps laboratories determine when results can be accepted and when corrective action is necessary.[65,66]

External quality control, commonly referred to as external quality assessment (EQA) or proficiency testing (PT), evaluates laboratory performance through samples supplied by independent organizations. Laboratories analyze these samples without knowing their assigned values and submit their findings for comparison with results from participating laboratories. This process helps identify analytical bias, assess comparability between laboratories, and evaluate compliance with established performance standards. However, the quality and suitability of the distributed materials must be considered when interpreting EQA/PT findings.[67] For ALP testing, the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) establish an acceptable proficiency-testing performance range of the target value ±30%. The College of American Pathologists applies the same acceptance criterion in its proficiency-testing surveys. Laboratories are expected to achieve at least 80% performance in each testing event for each analyte and maintain an overall score of 80% or higher across

analytes. In addition, each laboratory should establish acceptable limits for within-day and between-day variation according to the analytical instrument, method characteristics, and control materials used.[68,69] Laboratory safety is another essential component of the QMS. Every clinical laboratory should maintain a formal safety program that identifies occupational hazards, defines preventive measures, and establishes procedures for managing accidents and exposure incidents. These measures protect laboratory personnel, patients, and the surrounding environment while reducing the risk of specimen contamination and operational errors.[70]

Personal protective equipment (PPE), including gloves, laboratory coats or gowns, masks, and protective eyewear, should be available and used according to the level of exposure risk. During blood collection and specimen handling, disposable gloves provide an essential barrier against potentially infectious materials. Gloves must be changed between patients and discarded appropriately. Hand hygiene should be performed after glove removal and whenever personnel leave the work area. Facial protection is particularly important when procedures may generate splashes or aerosols containing blood or body fluids.[71] Needlestick and sharps injuries should be prevented through appropriate handling and disposal procedures. Syringes should be avoided when safer alternatives are available, and used needles must never be manually recapped or handled unnecessarily. All sharps should be discarded immediately into designated puncture-resistant containers. Protective clothing should be removed before leaving laboratory areas to prevent the transfer of potentially infectious materials. All patient specimens should be treated as potentially hazardous, regardless of whether warning labels are present. Appropriate biosafety level 2 practices should be followed when handling potentially infectious clinical materials.[72] Additional precautions include proper labeling and disposal of biological waste, routine cleaning of laboratory storage equipment, and safe handling of damaged specimen containers. Freezers and dry-ice storage units should be inspected periodically for broken tubes or ampoules containing biological materials. Personnel performing these cleaning activities should use suitable gloves and respiratory protection when exposure to biological hazards is possible.[73]

Occupational vaccination is another important preventive measure. The Occupational Safety and Health Administration requires employers to offer hepatitis B vaccination at no cost to employees with occupational exposure to blood or other potentially infectious materials. The Centers for Disease Control and Prevention and its Advisory Committee on Immunization Practices also recommend hepatitis B vaccination for healthcare and laboratory professionals, including medical technologists, phlebotomists, and pathologists. Laboratories should maintain appropriate vaccination records and provide access to occupational health services.[74] The ISO 15190 standard, introduced in 2003, provides specific guidance for establishing and maintaining safe working environments in medical laboratories. It addresses managerial responsibilities, personnel safety, fire prevention, radiation protection, and the management of laboratory hazards. The standard complements the principles of a QMS by emphasizing clearly defined responsibilities for laboratory directors, safety officers, and other employees. It also promotes staff training, documented procedures, regular safety audits, performance evaluation, and continuous improvement. Integrating ISO 15190 principles into laboratory practice supports consistent safety standards and strengthens the overall quality of diagnostic services.[75,76]

Enhancing Healthcare Team Outcomes

Alkaline phosphatase (ALP) testing is commonly requested during routine health assessments and investigations of suspected hepatobiliary or bone disorders. Accurate interpretation requires analytical reliability, clinical correlation, and effective collaboration among healthcare professionals. Misinterpretation of abnormal results may cause unnecessary investigations, delayed diagnosis, or inappropriate treatment. Therefore, coordinated interprofessional care is essential for improving diagnostic accuracy, patient safety, and resource utilization. Physicians and advanced practitioners assess the clinical indications for testing, correlate ALP results with patient symptoms, and determine the need for additional investigations, including gamma-glutamyl transferase (GGT), liver function tests, imaging, and bone turnover markers. Clinical pathologists and laboratory professionals ensure analytical quality, identify preanalytical and analytical interferences, and recommend appropriate follow-up investigations, such as ALP isoenzyme analysis. Nurses contribute through patient preparation, specimen collection, counseling, and monitoring for relevant clinical symptoms. Pharmacists review medication histories to identify drugs associated with cholestasis or altered bone metabolism. Interpretation must account for biological variation related to age, sex, and physiological status. Increased ALP is expected during childhood, adolescence, and pregnancy. Appropriate reference intervals should therefore be applied to avoid unnecessary concern or investigations. Standardized testing algorithms, reflex testing, interpretative laboratory comments, and multidisciplinary case discussions can reduce diagnostic uncertainty. Shared electronic medical records and structured communication support accurate reporting and coordinated follow-up. Patients with persistent abnormalities should receive appropriate reassessment and specialist referrals when indicated. Through shared responsibility,

effective communication, and integration of professional expertise, healthcare teams can improve ALP result interpretation, reduce diagnostic errors, promote patient-centered care, and achieve better clinical outcomes.

Conclusion:

Serum alkaline phosphatase is an important diagnostic marker in clinical laboratory medicine, particularly for identifying hepatobiliary abnormalities and disorders associated with increased bone turnover. Its clinical value depends on understanding its tissue-specific isoenzymes, physiological variations, analytical characteristics, and potential interfering factors. Combining ALP measurements with complementary tests, including GGT, 5'-nucleotidase, and isoenzyme analysis, improves diagnostic interpretation and helps establish the underlying source of abnormal activity. Reliable results also require appropriate specimen handling, validated analytical methods, effective quality control, and adherence to laboratory safety standards. Furthermore, collaboration among physicians, clinical pathologists, laboratory professionals, nurses, and pharmacists supports accurate diagnosis and appropriate patient management. Integrating these practices strengthens the diagnostic utility of ALP testing, reduces avoidable errors, and promotes evidence-based clinical decisions and improved patient outcomes.

References:

1. Green MR, Sambrook J. Alkaline Phosphatase. Cold Spring Harb Protoc. 2020 Aug 03;2020(8):100768.
2. Vimalraj S. Alkaline phosphatase: Structure, expression and its function in bone mineralization. Gene. 2020 Sep 05;754:144855.
3. Azpiazu D, Gonzalo S, Villa-Bellosta R. Tissue Non-Specific Alkaline Phosphatase and Vascular Calcification: A Potential Therapeutic Target. Curr Cardiol Rev. 2019;15(2):91-95.
4. Zaher DM, El-Gamal MI, Omar HA, Aljareh SN, Al-Shamma SA, Ali AJ, Zaib S, Iqbal J. Recent advances with alkaline phosphatase isoenzymes and their inhibitors. Arch Pharm (Weinheim). 2020 May;353(5):e2000011.
5. Lallès JP. Intestinal alkaline phosphatase: novel functions and protective effects. Nutr Rev. 2014 Feb;72(2):82-94.
6. Dixon IMC. Tissue non-specific alkaline phosphatase (TNAP): A player in post-MI cardiac fibrosis. EBioMedicine. 2021 Jun;68:103430.
7. Brichacek AL, Brown CM. Alkaline phosphatase: a potential biomarker for stroke and implications for treatment. Metab Brain Dis. 2019 Feb;34(1):3-19.
8. Crofton PM. Biochemistry of alkaline phosphatase isoenzymes. Crit Rev Clin Lab Sci. 1982;16(3):161-94.
9. Matsushita M, Harajiri S, Tabata S, Yukimasa N, Muramoto Y, Komoda T. [Alkaline phosphatase activity in blood group B or O secretors is fluctuated by the dinner intake of previous night]. Rinsho Byori. 2013 Apr;61(4):307-12.
10. Sharma U, Pal D, Prasad R. Alkaline phosphatase: an overview. Indian J Clin Biochem. 2014 Jul;29(3):269-78.
11. Masrour Roudsari J, Mahjoub S. Quantification and comparison of bone-specific alkaline phosphatase with two methods in normal and paget's specimens. Caspian J Intern Med. 2012 Summer;3(3):478-83.
12. Pike AF, Kramer NI, Blaauboer BJ, Seinen W, Brands R. A novel hypothesis for an alkaline phosphatase 'rescue' mechanism in the hepatic acute phase immune response. Biochim Biophys Acta. 2013 Dec;1832(12):2044-56.
13. Wieczorek E. [Nocturnal intragastric administration of phosphates in the treatment of familial hypophosphatemic rickets]. Pediatr Pol. 1986 Sep;61(9):563-70.
14. Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med. 2006;44(6):750-9.
15. McDonough PG. Pre-analytical errors: everything that happens to the specimen up to the point of testing. Fertil Steril. 2002 Apr;77(4):857-8.
16. Sancenon V, Goh WH, Sundaram A, Er KS, Johal N, Mukhina S, Carr G, Dhakshinamoorthy S. Development, validation and quantitative assessment of an enzymatic assay suitable for small molecule screening and profiling: A case-study. Biomol Detect Quantif. 2015 Jun;4:1-9.
17. Tietz NW, Burtis CA, Duncan P, Ervin K, Petitclerc CJ, Rinker AD, Shuey D, Zygowicz ER. A reference method for measurement of alkaline phosphatase activity in human serum. Clin Chem. 1983 May;29(5):751-61.
18. Hoekstra LT, de Graaf W, Nibourg GA, Heger M, Bennink RJ, Stieger B, van Gulik TM. Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg. 2013 Jan;257(1):27-36.
19. Siede WH, Seiffert UB. Quantitative alkaline phosphatase isoenzyme determination by electrophoresis on cellulose acetate membranes. Clin Chem. 1977 Jan;23(1):28-34.
20. Ni P, Xie J, Chen C, Jiang Y, Zhao Z, Zhang Y, Lu Y, Yu J. Spectrophotometric determination of the activity of alkaline phosphatase and detection of its inhibitors by exploiting the pyrophosphate-accelerated oxidase-like activity of nanoceria. Mikrochim Acta. 2019 May 02;186(5):320.
21. Wang J, Ni P, Chen C, Jiang Y, Zhang C, Wang B, Cao B, Lu Y. Colorimetric determination of the activity of alkaline phosphatase by exploiting the oxidase-like activity of palladium

cube@CeO_2 core-shell nanoparticles. Mikrochim Acta. 2020 Jan 09;187(2):115.
22. Warnes TW, Hine P, Kay G. Polyacrylamide gel disc electrophoresis of alkaline phosphatase isoenzymes in bone and liver disease. J Clin Pathol. 1976 Sep;29(9):782-7.
23. Milinković N, Sarić-Matutinović M, Pejanović S, Ignjatović S. Comparison between bone alkaline phosphatase immunoassay and electrophoresis technique in hemodialysis patients. J Med Biochem. 2020 Jan 23;39(2):178-183.
24. Rosalki SB, Foo AY. Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. Clin Chem. 1984 Jul;30(7):1182-6.
25. Moss DW. Alkaline phosphatase isoenzymes. Clin Chem. 1982 Oct;28(10):2007-16.
26. Iino S. [Clinical significance of alkaline phosphatase isozyme analysis]. Nihon Rinsho. 1995 May;53(5):1157-61.
27. Farley JR, Hall SL, Herring S, Libanati C, Wergedal JE. Reference standards for quantification of skeletal alkaline phosphatase activity in serum by heat inactivation and lectin precipitation. Clin Chem. 1993 Sep;39(9):1878-84.
28. Puukka R. Comparison of alkaline phosphatase isoenzymes determined by an inhibition method and by electrophoresis. Clin Chim Acta. 1978 Apr 17;85(2):111-4.
29. Fishman WH. Immunology and biochemistry of the Regan isoenzyme. Prostate. 1980;1(4):399-410.
30. Moss DW. Diagnostic aspects of alkaline phosphatase and its isoenzymes. Clin Biochem. 1987 Aug;20(4):225-30.
31. Nozawa S, Arai H, Widjaja T, Tsukazaki K, Ohta H, Kurihara S. [Biochemical studies on alkaline phosphatase isoenzyme profile in endometrial cancer]. Nihon Sanka Fujinka Gakkai Zasshi. 1984 Mar;36(3):369-76.
32. Jardillier JC. [The isoenzymes of the alkaline phosphatases and their cancerologic biochemistries prospects (author's transl)]. Ann Biol Clin (Paris). 1981;39(3):115-20.
33. Bowen RA, Remaley AT. Interferences from blood collection tube components on clinical chemistry assays. Biochem Med (Zagreb). 2014;24(1):31-44.
34. Knaak JB, Leung HW, Stott WT, Busch J, Bilsky J. Toxicology of mono-, di-, and triethanolamine. Rev Environ Contam Toxicol. 1997;149:1-86.
35. Niina N, Kodamatani H, Uozumi K, Kokufu Y, Saito K, Yamazaki S. Simultaneous detection of monoethanolamine, diethanolamine, and triethanolamine by HPLC with a chemiluminescence reaction and online derivatization to tertiary amine. Anal Sci. 2005 May;21(5):497-500.
36. Horning K, Schmidt C. Azathioprine-Induced Rapid Hepatotoxicity. J Pharm Technol. 2014 Feb;30(1):18-20.
37. Fraser MO, Arslan M, Plant TM. Androgen and estrogen treatment, alone or in combination, differentially influences bone maturation and hypothalamic mechanisms that time puberty in the male rhesus monkey (Macaca mulatta). Pediatr Res. 2005 Jan;57(1):141-8.
38. Sjödén G, Rosenqvist M, Kriegholm E, Nordenström J, Björkhem I. Verapamil increases serum alkaline phosphatase in hypertensive patients. J Intern Med. 1990 Oct;228(4):339-42.
39. David S, Hamilton JP. Drug-induced Liver Injury. US Gastroenterol Hepatol Rev. 2010 Jan 01;6:73-80.
40. Wang Z, Guo H, Wang Y, Kong F, Wang R. Interfering effect of bilirubin on the determination of alkaline phosphatase. Int J Clin Exp Med. 2014;7(11):4244-8.
41. Pyles LA, Stejskal EJ, Einzig S. Spectrophotometric measurement of plasma 2-thiobarbituric acid-reactive substances in the presence of hemoglobin and bilirubin interference. Proc Soc Exp Biol Med. 1993 Apr;202(4):407-19.
42. Stigbrand T. Present status and future trends of human alkaline phosphatases. Prog Clin Biol Res. 1984;166:3-14.
43. Martin JM, Goldberg DM. Activities of gamma-glutamyl transferase, 5'-nucleotidase and alkaline phosphatase in human duodenal aspirate. Enzyme. 1986;35(4):189-96.
44. Takeuchi A, Shibuya A. [5'-Nucleotidase]. Nihon Rinsho. 1999 Aug;57 Suppl:483-5.
45. Shamban L, Patel B, Williams M. Significantly Elevated Liver Alkaline Phosphatase in Congestive Heart Failure. Gastroenterology Res. 2014 Apr;7(2):64-68.
46. Gao Y, Chin K, Mishriki YY. AIDS Cholangiopathy in an Asymptomatic, Previously Undiagnosed Late-Stage HIV-Positive Patient from Kenya. Int J Hepatol. 2011;2011:465895.
47. Šmíd V. Liver tests. Cas Lek Cesk. 2022 Spring;161(2):52-56.
48. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer. 2000 Jun 15;88(12 Suppl):2919-26.
49. Fontes-Sousa M, Magalhães H, da Silva FC, Maurício MJ. Stauffer's syndrome: A comprehensive review and proposed updated diagnostic criteria. Urol Oncol. 2018 Jul;36(7):321-326.
50. Sakurai Y, Higashiguchi T. Transient hyperphosphatasemia: Possible association with pediatric acute respiratory infection. Pediatr Investig. 2021 Jun;5(2):94-98.
51. Whyte MP. Hypophosphatasia: An overview For 2017. Bone. 2017 Sep;102:15-25.

52. Arthur LJ, Hill PG, Attenburrow AA. Transient hyperphosphatasaemia. Arch Dis Child. 1984 Oct;59(10):996-7.
53. Schonhaut B L, Rocha R A. [Benign transient hyperphosphatasaemia in infants: Clinical series]. Rev Chil Pediatr. 2017 Feb;88(1):169-175.
54. Verma J, Gorard DA. Persistently elevated alkaline phosphatase. BMJ Case Rep. 2012 Aug 24;2012
55. Assy N, Jacob G, Spira G, Edoute Y. Diagnostic approach to patients with cholestatic jaundice. World J Gastroenterol. 1999 Jun;5(3):252-262.
56. Revzin MV, Scoutt LM, Garner JG, Moore CL. Right Upper Quadrant Pain: Ultrasound First! J Ultrasound Med. 2017 Oct;36(10):1975-1985.
57. Siddique A, Kowdley KV. Approach to a patient with elevated serum alkaline phosphatase. Clin Liver Dis. 2012 May;16(2):199-229.
58. Wadhwa V, Rai S, Thukral T, Chopra M. Laboratory quality management system: road to accreditation and beyond. Indian J Med Microbiol. 2012 Apr-Jun;30(2):131-40.
59. Allen LC. Role of a quality management system in improving patient safety - laboratory aspects. Clin Biochem. 2013 Sep;46(13-14):1187-93.
60. Ricós C, Fernandez-Calle P, Perich C, Westgard JO. Internal quality control - past, present and future trends. Adv Lab Med. 2022 Oct;3(3):243-262.
61. Loh TP, Lim CY, Sethi SK, Tan RZ, Markus C. Advances in internal quality control. Crit Rev Clin Lab Sci. 2023 Nov;60(7):502-517.
62. Kinns H, Pitkin S, Housley D, Freedman DB. Internal quality control: best practice. J Clin Pathol. 2013 Dec;66(12):1027-32.
63. Yago M, Pla C. Reference-mean-centered statistical quality control. Clin Chem Lab Med. 2020 Aug 27;58(9):1517-1523.
64. Bruno LC. IQCP: Guideline and Helpful Tools for Implementation. Lab Med. 2016 Nov;47(4):e42-e46.
65. Khatri R, K C S, Shrestha P, Sinha JN. Implementing self sustained quality control procedures in a clinical laboratory. JNMA J Nepal Med Assoc. 2013 Jan-Mar;52(189):233-7.
66. Poh DKH, Lim CY, Tan RZ, Markus C, Loh TP. Internal quality control: Moving average algorithms outperform Westgard rules. Clin Biochem. 2021 Dec;98:63-69.
67. James D, Ames D, Lopez B, Still R, Simpson W, Twomey P. External quality assessment: best practice. J Clin Pathol. 2014 Aug;67(8):651-5.
68. Born PH, Thran SL. The influence of CLIA '88 on physician office laboratories. J Fam Pract. 1998 Apr;46(4):319-27.
69. Badrick T. Integrating quality control and external quality assurance. Clin Biochem. 2021 Sep;95:15-27.
70. Keckler MS, Anderson K, McAllister S, Rasheed JK, Noble-Wang J. Development and implementation of evidence-based laboratory safety management tools for a public health laboratory. Saf Sci. 2019 Aug;117:205-216.
71. Ialongo C, Bernardini S. Phlebotomy, a bridge between laboratory and patient. Biochem Med (Zagreb). 2016;26(1):17-33.
72. Tice AD. Bloodborne pathogen exposure and recommendations for management. J Infus Nurs. 2002 Nov-Dec;25(6 Suppl):S5-9.
73. Ta L, Gosa L, Nathanson DA. Biosafety and Biohazards: Understanding Biosafety Levels and Meeting Safety Requirements of a Biobank. Methods Mol Biol. 2019;1897:213-225.
74. Byrd KK, Lu PJ, Murphy TV. Hepatitis B vaccination coverage among health-care personnel in the United States. Public Health Rep. 2013 Nov-Dec;128(6):498-509.
75. Noble MA. ISO 15190:2003 Medical Laboratories - Requirements for Safety. EJIFCC. 2004 Dec;15(4):141-143.

Orelle A, Nikiema A, Zakaryan A, Albetkova AA, Keita MS, Rayfield MA, Peruski LF, Pierson A. A Multilingual Tool for Standardized Laboratory Biosafety and Biosecurity Assessment and Monitoring. Health Secur. 2022 Nov-Dec;20(6):488-496